Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that adults with seborrheic ...

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature Suggests skin barrier disruption in seborrheic dermatitis is distinct with its own ...

Seborrheic dermatitis may be linked to various epithelial barrier diseases (EBDs) affecting multiple organ systems and ultimately a key factor when addressing epithelial barrier weakness and ...

Discover a study revealing how seborrheic dermatitis is linked to multiple epithelial barrier diseases, supporting the ...

There are a few ingredients that can help treat dry patches. “I advise patients to look for products that contain hyaluronic ...

Findings show that seborrheic dermatitis is a unique inflammatory skin disease with its own molecular signature Suggests skin barrier disruption in seborrheic dermatitis is distinct with its own ...

Seborrheic dermatitis is linked to other epithelial barrier diseases, supporting the epithelial barrier theory as a shared pathogenesis driver. Positive associations were found with atopic dermatitis, ...

Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...